Literature DB >> 10806206

Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome.

G Schmidtke1, S Emch, M Groettrup, H G Holzhutter.   

Abstract

The 20 S proteasome is an endoprotease complex that preferentially cleaves peptides C-terminal of hydrophobic, basic, and acidic residues. Recently, we showed that these specific activities, classified as chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide-hydrolyzing (PGPH) activity, are differently affected by Ritonavir, an inhibitor of human immunodeficiency virus-1 protease. Ritonavir competitively inhibited the chymotrypsin-like activity, whereas the trypsin-like activity was enhanced. Here we demonstrate that the Ritonavir-mediated up-regulation of the trypsin-like activity is not affected by specific active site inhibitors of the chymo-trypsin-like and PGPH activity. Moreover, we show that the mutual regulation of chymotrypsin-like and PGPH activities by their substrates as described previously by a "cyclical bite-chew" model is not affected by selective inhibitors of the respective active sites. These data challenge the bite-chew model and suggest that effectors of proteasome activity can act by binding to non-catalytic sites. Accordingly, we propose a kinetic "two-site modifier" model that assumes that the substrate (or effector) may bind to an active site as well as to a second non-catalytic modifier site. This model appears to be valid as it describes the complex kinetic effects of Ritonavir very well. Since Ritonavir partially inhibits major histocompatibility complex class I restricted antigen presentation, the postulated modifier site may be required to coordinate the active centers of the proteasome for the production of class I peptide ligands.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806206     DOI: 10.1074/jbc.M002513200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.

Authors:  Lloyd D Fricker; Julia S Gelman; Leandro M Castro; Fabio C Gozzo; Emer S Ferro
Journal:  J Proteome Res       Date:  2012-02-16       Impact factor: 4.466

2.  A mathematical model of protein degradation by the proteasome.

Authors:  Fabio Luciani; Can Keşmir; Michele Mishto; Michal Or-Guil; Rob J de Boer
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

3.  Lysine 188 substitutions convert the pattern of proteasome activation by REGgamma to that of REGs alpha and beta.

Authors:  J Li; X Gao; J Ortega; T Nazif; L Joss; M Bogyo; A C Steven; M Rechsteiner
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

4.  Polyubiquitin substrates allosterically activate their own degradation by the 26S proteasome.

Authors:  Dawadschargal Bech-Otschir; Annett Helfrich; Cordula Enenkel; Gesa Consiglieri; Michael Seeger; Hermann-Georg Holzhütter; Burkhardt Dahlmann; Peter-Michael Kloetzel
Journal:  Nat Struct Mol Biol       Date:  2009-01-25       Impact factor: 15.369

5.  Optimal length transportation hypothesis to model proteasome product size distribution.

Authors:  Alexey Zaikin; Juergen Kurths
Journal:  J Biol Phys       Date:  2006-10-26       Impact factor: 1.365

6.  Proteasome allostery as a population shift between interchanging conformers.

Authors:  Amy M Ruschak; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

Review 7.  Harnessing proteasome dynamics and allostery in drug design.

Authors:  Maria Gaczynska; Pawel A Osmulski
Journal:  Antioxid Redox Signal       Date:  2014-02-21       Impact factor: 8.401

Review 8.  Proteasome Biology: Chemistry and Bioengineering Insights.

Authors:  Lucia Račková; Erika Csekes
Journal:  Polymers (Basel)       Date:  2020-12-04       Impact factor: 4.329

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel.

Authors:  Pawel A Osmulski; Mark Hochstrasser; Maria Gaczynska
Journal:  Structure       Date:  2009-08-12       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.